Key result
MitraClip XTR and PASCAL show comparable short-term outcomes for severe tricuspid regurgitation.
Why the study?
Edge-to-edge repair of severe tricuspid regurgitation is an alternative treatment for inoperable patients, but comparative data between MitraClip XTR and PASCAL systems are limited.
Does the MitraClip XTR system improve acute and short-term results compared to the PASCAL system in inoperable patients with severe tricuspid regurgitation?
Does the MitraClip XTR system improve acute and short-term results compared to the PASCAL system in inoperable patients with severe tricuspid regurgitation?
Both devices yield high procedural success and comparable safety in severe TR; leaves open optimal device selection pending randomized trials.
Edge-to-Edge repair of severe tricuspid regurgitation (TR) is an alternative treatment option for inoperable patients. We compared the acute and short-term results of patients treated with the MitraClip XTR (Abbott Vascular) vs. PASCAL (Edwards Lifesciences) system. We retrospectively analysed 120
No takes yet. Share an insight, caveat, or question.
Braun et al. (2020) studied this question. MitraClip XTR and PASCAL transcatheter edge-to-edge repair systems were retrospectively compared in 120 patients with severe tricuspid regurgitation, though the abstract truncates before reporting res.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: